2. Academic Validation
  3. Antiviral Activity of Hederasaponin B from Hedera helix against Enterovirus 71 Subgenotypes C3 and C4a

Antiviral Activity of Hederasaponin B from Hedera helix against Enterovirus 71 Subgenotypes C3 and C4a

  • Biomol Ther (Seoul). 2014 Jan;22(1):41-6. doi: 10.4062/biomolther.2013.108.
Jaehyoung Song 1,  Sang-Gu Yeo 2,  Eun-Hye Hong 3,  Bo-Ra Lee 3,  Jin-Won Kim 4,  Jeonghoon Kim 5,  Hyeongun Jeong 5,  Yongsoo Kwon 3,  Hyunpyo Kim 3,  Sangwon Lee 4,  Jae-Hak Park 6,  Hyun-Jeong Ko 3
Affiliations

Affiliations

  • 1 Division of Vaccine Research, Center for Infectious Diseases, National Institute of Health, Korea Centers for Diseases Control and Prevention, Osong 363-951 ; College of Pharmacy, Kangwon National University, Chuncheon 200-701.
  • 2 Division of Vaccine Research, Center for Infectious Diseases, National Institute of Health, Korea Centers for Diseases Control and Prevention, Osong 363-951 ; Laboratory Animal Medicine, College of Veterinary Medicine, Seoul National University, Seoul 151-742.
  • 3 College of Pharmacy, Kangwon National University, Chuncheon 200-701.
  • 4 Division of Vaccine Research, Center for Infectious Diseases, National Institute of Health, Korea Centers for Diseases Control and Prevention, Osong 363-951.
  • 5 Ahn-Gook Pharmaceutical Co., LTD, Seoul 150-953, Republic of Korea.
  • 6 Laboratory Animal Medicine, College of Veterinary Medicine, Seoul National University, Seoul 151-742.
PMID: 24596620 DOI: 10.4062/biomolther.2013.108
Abstract

Enterovirus 71 (EV71) is the predominant cause of hand, foot and mouth disease (HFMD). The Antiviral activity of hederasaponin B from Hedera helix against EV71 subgenotypes C3 and C4a was evaluated in vero cells. In the current study, the Antiviral activity of hederasaponin B against EV71 C3 and C4a was determined by cytopathic effect (CPE) reduction method and western blot assay. Our results demonstrated that hederasaponin B and 30% ethanol extract of Hedera helix containing hederasaponin B showed significant Antiviral activity against EV71 subgenotypes C3 and C4a by reducing the formation of a visible CPE. Hederasaponin B also inhibited the viral VP2 protein expression, suggesting the inhibition of viral capsid protein synthesis.These results suggest that hederasaponin B and Hedera helix extract containing hederasaponin B can be novel drug candidates with broad-spectrum Antiviral activity against various subgenotypes of EV71.

Keywords

Antiviral activity; Enterovirus 71; Hand foot and mouth disease; Hedera helix; Hederasaponin B.

Figures
Products